CambridgeSoft, a provider of e-notebook solutions has entered into an agreement with AstraZeneca to deploy its industry leading E-Notebook software to 1000 scientists around the world
AstraZeneca engaged CambridgeSoft in a global ten-site proof of concept, incorporating the input of over 100 research scientists.
The award winning CambridgeSoft E-Notebook was selected as a result of its ability to meet the specialized data needs of the organization's discovery medicinal chemists.
A joint global team will integrate key discovery applications and workflows to meet the present and future, diverse needs of these scientists.
"CambridgeSoft is excited to be selected after the rigorous analysis by the AstraZeneca evaluation team.
"We look forward to a quick return on AstraZeneca's investment in our technology", said Michael Tomasic, chairman and CEO, CambridgeSoft.
CambridgeSoft develops and markets life science enterprise solutions for pharmaceutical, biotechnology, chemical companies and academic research organizations.
Software products include enterprise, workgroup, and desktop versions of Chem and Bio Office, including ChemDraw, with knowledge management, chemical and biological informatics, and scientific database solutions.
